# Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT00522938** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chroma Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** CHR-2797 (tosedostat)
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00522938
- **Lead sponsor:** Chroma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2008-02
- **Final completion:** 2008-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Very poor recruitment of patients to the study
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522938, "Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00522938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*